每经头条（nbdtoutiao）——海南封关首日直击：为中国探路，全球最大自贸港如何重塑开放边界？ 截至发稿，益方生物市值为171亿元。 每经AI快讯，益方生物（SH 688382，收盘价：29.5元）12月19日晚间发布公告称，本激励计划涉及的 激励对象共计179人，拟授出权益涉及的标的股票来源及种类本激励计划涉及的标的股票来源为公司向 激励对象定向发行的本公司人民币A股普通股股票；拟授予激励对象的限制性股票数量为557.7万股，约 占本激励计划草案公布日公司股本总额约5.78亿股的0.96%；限制性股票的授予价格为每股16.87元，即 满足授予条件和归属条件后，激励对象可以每股16.87元的价格购买公司股票，的有效期为自限制性股 票授予日起至激励对象获授的限制性股票全部归属或作废失效之日止，最长不超过60个月。 2024年1至12月份，益方生物的营业收入构成为：医药制造业占比100.0%。 （记者 曾健辉） ...

Group 1 - The core point of the article is that Duori Pharmaceutical announced a share repurchase plan, allowing the company to sell back its repurchased shares within a specified timeframe [1] - The company plans to sell up to approximately 1.04 million shares, which represents 1.31% of its total share capital, with the sale price determined by the secondary market [1] - The board meeting to approve this plan is scheduled for December 19, 2025, and the sale period will be from January 14, 2026, to July 13, 2026 [1] Group 2 - For the year 2024, Duori Pharmaceutical's revenue composition is 57.85% from the pharmaceutical manufacturing sector and 42.15% from other sources [1] - As of the latest report, the market capitalization of Duori Pharmaceutical is 4.1 billion yuan [2]

每经AI快讯，益方生物（SH 688382，收盘价：29.5元）12月19日晚间发布公告称，公司第二届2025年 第九次董事会会议于2025年12月19日以现场结合通讯形式召开。会议审议了《关于提请召开2026年第一 次临时股东会的议案》等文件。 2024年1至12月份，益方生物的营业收入构成为：医药制造业占比100.0%。 截至发稿，益方生物市值为171亿元。 每经头条（nbdtoutiao）——海南封关首日直击：为中国探路，全球最大自贸港如何重塑开放边界？ （记者 曾健辉） ...

截至发稿，以岭药业市值为293亿元。 每经AI快讯，以岭药业（SZ 002603，收盘价：17.56元）12月19日晚间发布公告称，公司接到公司实际 控制人吴瑞的通知，获悉吴瑞所持有本公司的部分股份办理质押展期，本次质押展期股份726万股。截 至本公告日，吴相君累计质押股数为1500万股，占其所持股份比例为4.31%。吴瑞累计质押股数为899 万股，占其所持股份比例为22.99%。 每经头条（nbdtoutiao）——海南封关首日直击：为中国探路，全球最大自贸港如何重塑开放边界？ 2025年1至6月份，以岭药业的营业收入构成为：医药制造业占比100.0%。 （记者 王晓波） ...

Core Viewpoint - The economic performance of the province from January to November shows steady growth in industrial output, expanding market sales, and rapid export growth, indicating overall economic stability [1] Industrial Performance - The province's industrial added value increased by 1.1% year-on-year, with high-tech manufacturing growing by 3.3% [1] - Mining industry added value rose by 6.8%, while manufacturing grew by 0.5%, and the electricity, heat, gas, and water production and supply sector declined by 1.6% [1] - Among 40 major industrial sectors, 23 experienced year-on-year growth, resulting in a growth rate of 57.5% [1] - Notable growth sectors include chemical fiber manufacturing (up 7.3 times), transportation equipment manufacturing (up 41%), and non-ferrous metal mining (up 17.6%) [1] Product Performance - Civil steel ship production increased by 88.3%, transformers by 48%, and synthetic ammonia by 21.2% [2] - Sales of wearable smart devices surged by 16.3 times, while energy-efficient home appliances and smartphones both grew by 1.1 times [3] Investment and Sales - Investment in high-tech manufacturing rose by 14.1%, indicating strong growth in this sector [3] - The total retail sales of consumer goods reached 956.5 billion yuan, with a year-on-year growth of 2.3% [3] - Basic living goods saw stable sales growth, with food retail up by 12.2% and daily necessities by 9.3% [3] Export Performance - The province's total import and export value reached 684.07 billion yuan, with exports at 373.48 billion yuan, growing by 9.4% [3] - Key export products included agricultural products (310.5 billion yuan, up 9.2%) and electromechanical products (1,891.2 billion yuan, up 9.3%) [3]

企业名称海南昱维医药有限公司法定代表人赵贺军注册资本300万人民币国标行业制造业>医药制造业> 化学药品制剂制造地址海南省澄迈县老城镇南一环路南侧海南生态软件园C地块二期工程C40栋一层106 室企业类型有限责任公司（非自然人投资或控股的法人独资）营业期限2025-12-18至无固定期限登记机 关海南省市场监督管理局 天眼查显示，近日，海南昱维医药有限公司成立，法定代表人为赵贺军，注册资本300万人民币，由上 海汇优智华企业管理有限责任公司全资持股。 序号股东名称持股比例1上海汇优智华企业管理有限责任公司100% 经营范围含许可经营项目：药品批发；食品销售；第三类医疗器械经营；住宅室内装饰装修（许可经营 项目凭许可证件经营）一般经营项目：第一类医疗器械销售；第二类医疗器械销售；信息咨询服务（不 含许可类信息咨询服务）；信息技术咨询服务；个人商务服务；会议及展览服务；货物进出口；技术进 出口；日用百货销售；劳动保护用品销售；针纺织品销售；服装服饰零售；鞋帽零售；皮革制品销售； 五金产品零售；建筑材料销售；建筑装饰材料销售；电工器材销售；制冷、空调设备销售；销售代理； 化工产品销售（不含许可类化工产品）；化妆品零 ...

经营范围含许可经营项目：第三类医疗器械经营；第三类医疗设备租赁；医疗器械互联网信息服务；药 品零售；药品批发；药品进出口（许可经营项目凭许可证件经营）一般经营项目：生物化工产品技术研 发；生物饲料研发；生物基材料技术研发；技术服务、技术开发、技术咨询、技术交流、技术转让、技 术推广；医学研究和试验发展；工程和技术研究和试验发展；生物基材料销售；生物质能技术服务；细 胞技术研发和应用；新材料技术研发；人体干细胞技术开发和应用；第一类医疗器械销售；第一类医疗 设备租赁；医护人员防护用品批发；医护人员防护用品零售；个人卫生用品销售；卫生用品和一次性使 用医疗用品销售；实验分析仪器销售；智能仪器仪表销售；仪器仪表销售；药物检测仪器销售；玻璃仪 器销售；教学专用仪器销售；光学仪器销售；化工产品销售（不含许可类化工产品）；消毒剂销售（不 含危险化学品）；日用化学产品销售；教学用模型及教具销售；办公用品销售；贸易经纪；离岸贸易经 营；国内贸易代理；销售代理；第二类医疗器械销售；第二类医疗设备租赁；医用口罩零售；医用口罩 批发；特殊医学用途配方食品销售；食品销售（仅销售预包装食品）；保健食品（预包装）销售；食品 互联网销售（ ...

Group 1 - New stock offerings include Qiangyi Co. with an issuance price of 85.09 CNY per share and a subscription limit of 0.75 million shares, Yufan Technology at 22.29 CNY per share with a limit of 0.85 million shares, and Shuangxin Environmental Protection at 6.85 CNY per share with a limit of 60 million shares [2] - The Ministry of Commerce announced that some Chinese exporters have met the basic requirements for applying for general licenses regarding rare earth export controls, with some applications already approved [3] - The Hong Kong Stock Exchange is proposing a new trading unit framework to enhance market efficiency and reduce investment thresholds, which includes lowering the minimum value for trading units from 2000 HKD to 1000 HKD [4] Group 2 - The State Council issued guidelines to combat illegal activities related to tobacco, aiming to address issues such as counterfeiting and smuggling [4] - The State-owned Assets Supervision and Administration Commission released measures for accountability in investment violations, categorizing asset losses and defining responsibilities based on severity [5] - The Ministry of Industry and Information Technology announced that the photovoltaic industry will enter a critical governance phase by 2026, focusing on capacity regulation and management of manufacturing projects [5] Group 3 - The Bank of England announced a reduction in the benchmark interest rate from 4% to 3.75%, marking the lowest rate since February 2023 [6] - Haitian Flavor Industry plans to distribute a special dividend of 3 CNY per share [8] - Sichuan Road and Bridge has been acquired by Zhongyou Insurance, reaching a 5% shareholding [8]

Group 1 - The core point of the article is the appointment of Dr. Wang Lai as the new president and global head of R&D for BeiGene, which was approved by the company's board of directors [1] - For the year 2024, BeiGene's revenue composition is entirely from the pharmaceutical manufacturing industry, accounting for 100.0% [1] - As of the report, BeiGene's market capitalization stands at 418.6 billion yuan [1]

Group 1 - Zhejiang Lingyu Pharmaceutical Co., Ltd. was recently established with a registered capital of 100 million RMB, focusing on drug production, wholesale, and technology import/export [1][2] - The legal representative of the company is Zhang Hongyao, and it is co-owned by Zhejiang Shengzhao Pharmaceutical Technology Co., Ltd. (55% stake) and Hisun Pharmaceutical Co., Ltd. (45% stake) [1][2] - The company is registered in Taizhou, Zhejiang Province, and its business scope includes drug production and wholesale, subject to regulatory approvals [1][2]